Table 2.
Baseline characteristics of the propensity score-matched cohort in 180 days before the index date
| Allopurinol initiators (N= 90,358) | Allopurinol non-users (N= 90,358) | |
|---|---|---|
|
Demographic characteristics
| ||
| Age (year), mean (SD) | 65.5 (15.6) | 65.6 (15.5) |
| Male, n (%) | 47,278 (52.3) | 47,278 (52.3) |
| White, n (%) | 37,403 (41.4) | 37,108 (41.1) |
|
| ||
|
Health care utilization
| ||
| No. of outpatient visit, mean (SD) | 27.0 (32.4) | 22.9 (30.6) |
| 1 or more ER visits, n (%) | 32,827 (36.3) | 31,000 (34.3) |
| No. of all prescription drugs, mean (SD) | 6.9 (4.9) | 5.7 (4.8) |
| 1 or more hospitalization, n (%) | 22,919 (25.4) | 20,607 (22.8) |
|
| ||
|
Comorbidities
| ||
| Comorbidity Index, mean (SD) | 1.9 (2.1) | 1.5 (1.9) |
| Diabetes mellitus, n (%) | 16,942 (18.8) | 14,727 (16.3) |
| Gout, n (%) | 9,095 (10.1) | 355 (0.4) |
| Liver disease, n (%) | 1,581 (1.8) | 1,760 (2.0) |
| Kidney disease, n (%) | 5,356 (5.9) | 3,117 (3.5) |
| Nephrolithiasis, n (%) | 2,024 (2.2) | 4,309 (4.8) |
| Hypertension, n (%) | 29,419 (32.6) | 23,970 (26.5) |
| Heart failure, n (%) | 12,209 (13.5) | 8,017 (8.9) |
| Coronary artery disease, n (%) | 10,445 (11.6) | 9,447 (10.5) |
| COPD, n (%) | 9,843 (10.9) | 9,449 (10.5) |
SD: standard deviation, ER: emergency room, COPD: chronic obstructive pulmonary disease